Latest Health News
PetMeds Extends Existing Shareholder Rights Plan
November 26, 2025 16:05 ET | Source: PetMed Express, Inc. DELRAY BEACH,…
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq:…
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
$4.25 million upfront with up to an additional $4.1 million of potential…
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
November 25, 2025 18:15 ET | Source: Ascendis Pharma – Prescription Drug…
KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated…
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
The Company continues working with the third-party manufacturer to address recent FDA…
Pennsylvania Perio & Implants Announces Strengthened Commitment to Evidence-Based Periodontal and Dental Implant Evaluation in Pennsylvania
York, Pennsylvania, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Pennsylvania Perio & Implants…
Junshi Biosciences Announces Primary Endpoints Met in JS001scs Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Natures Signal Transduction and Targeted Therapy
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE,…
